Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...
New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback